Literature DB >> 2586750

Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

I J Mitchell1, C E Clarke, S Boyce, R G Robertson, D Peggs, M A Sambrook, A R Crossman.   

Abstract

The 2-deoxyglucose metabolic mapping technique has been used to investigate the neural mechanisms which underlie the symptoms of Parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease. In six cynomolgus monkeys, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine was either (a) administered intravenously to induce generalized Parkinsonism, or (b) infused into one carotid artery to induce unilateral Parkinsonism. Post-mortem examination revealed profound cell loss from the substantia nigra, pars compacta either bilaterally or unilaterally in the two groups, respectively. In addition, there was pathological involvement of the ventral tegmental area and locus coeruleus in animals receiving intravenous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 2-Deoxyglucose autoradiography revealed widespread changes in 2-deoxyglucose uptake in the brains of parkinsonian animals when compared to controls. Most of these changes were in basal ganglia and related structures and were qualitatively similar in the two groups of experimental animals. Prominent increases in 2-deoxyglucose uptake were observed in the lateral segment of the globus pallidus (24-27%), the ventral anterior and ventral lateral nuclei of the thalamus (14-22%) and the nucleus tegmenti pedunculopontinus of the caudal midbrain (17-69%). A profound decrease (17-26%) in 2-deoxyglucose uptake was observed in the subthalamic nucleus. We propose these data to indicate that in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism there is the following pattern of abnormal neuronal activity in basal ganglia circuitry: (i) increased activity in the projection from the putamen to the lateral segment of the globus pallidus; (ii) decreased activity in the projection from the putamen to the medial segment of the globus pallidus; (iii) decreased activity in the projection from the lateral segment of the globus pallidus to the subthalamic nucleus; (iv) increased activity in the projection from the subthalamic nucleus to the globus pallidus; and (v) increased activity in neurons of the medial segment of the globus pallidus projecting to the ventral anterior/ventral lateral thalamus and the pedunculopontine nucleus. These results are compared to the 2-deoxyglucose uptake findings in previous studies from this laboratory in hemiballism and hemichorea in the monkey. The central importance of the subthalamic nucleus in all three conditions is proposed, and supportive evidence for the excitatory nature of subthalamic efferent fibres is adduced.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2586750     DOI: 10.1016/0306-4522(89)90120-6

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  59 in total

1.  Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism.

Authors:  Yilong Ma; Shichun Peng; Phoebe G Spetsieris; Vesna Sossi; David Eidelberg; Doris J Doudet
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-30       Impact factor: 6.200

Review 2.  The pedunculopontine nucleus as a target for deep brain stimulation.

Authors:  Clement Hamani; Elena Moro; Andres M Lozano
Journal:  J Neural Transm (Vienna)       Date:  2010-12-31       Impact factor: 3.575

3.  Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity.

Authors:  K K Gnanalingham; N A Milkowski; L A Smith; A J Hunter; P Jenner; C D Marsden
Journal:  J Neural Transm Gen Sect       Date:  1995

4.  Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.

Authors:  Yilong Ma; Tom H Johnston; Shichun Peng; Chuantao Zuo; James B Koprich; Susan H Fox; Yihui Guan; David Eidelberg; Jonathan M Brotchie
Journal:  Mov Disord       Date:  2015-08       Impact factor: 10.338

Review 5.  The pedunculopontine tegmental nucleus and experimental parkinsonism. A review.

Authors:  Masaru Matsumura
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

6.  Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.

Authors:  Jordi Bové; Jordi Serrats; Guadalupe Mengod; Roser Cortés; Eduardo Tolosa; Concepció Marin
Journal:  Exp Brain Res       Date:  2005-06-21       Impact factor: 1.972

Review 7.  Dichotomy between motor and cognitive functions of midbrain cholinergic neurons.

Authors:  Nadine K Gut; Juan Mena-Segovia
Journal:  Neurobiol Dis       Date:  2018-09-10       Impact factor: 5.996

8.  Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine.

Authors:  T R K Varma; S H Fox; P R Eldridge; P Littlechild; P Byrne; A Forster; A Marshall; H Cameron; K McIver; N Fletcher; M Steiger
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

9.  Antiparkinsonian effect of flupirtine in monoamine-depleted rats.

Authors:  M Schwarz; M Nolden-Koch; J Purr; G Pergande; F Block
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

10.  The competitive NMDA antagonists CGP 43487 and APV potentiate dopaminergic function.

Authors:  R Dall'Olio; R Rimondini; O Gandolfi
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.